An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 11, 2024

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions
Beta-Thalassemia
Interventions
DRUG

Vebeglogene autotemcel

Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.

Trial Locations (2)

650100

RECRUITING

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming

650200

RECRUITING

Kunming Hope of Health Hospital, Kunming

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Lantu Biopharma

INDUSTRY